Influenza A virus (H1N1) 2009 hemagglutinin and neuraminidase (HA and NA (H1N1pdm09))

The Influenza A virus (H1N1) 2009 hemagglutinin (HA) and neuraminidase (NA) are the primary surface glycoproteins of the H1N1pdm09 virus, which was responsible for the 2009 swine flu pandemic. Hemagglutinin mediates viral entry by binding to host cell sialic acid receptors and facilitating membrane fusion in the endosome, while neuraminidase is an enzyme that cleaves sialic acid to allow the release of newly formed virions from the host cell surface. These proteins are the central targets for both the host immune system and medical countermeasures; vaccines primarily target the HA head to induce neutralizing antibodies, whereas antiviral drugs like oseltamivir and zanamivir inhibit the NA enzyme to prevent viral spread. A critical functional balance between HA's binding affinity and NA's enzymatic activity is required for optimal viral fitness and human-to-human transmission. Continuous monitoring of these targets is necessary due to the risk of antigenic drift and the emergence of drug-resistant mutations, such as the H275Y substitution in the neuraminidase protein.

Other names

H1N1pdm09 HAH1N1pdm09 NASwine flu antigensHemagglutinin (H1)Neuraminidase (N1)A/H1N1pdm09 surface glycoproteinsA/California/04/2009 HA/NA

Neuraminidase inhibitors (e.g., oseltamivir) block the enzymatic site of NA to prevent the cleavage of sialic acid, thereby trapping progeny virions on the host cell; Hemagglutinin inhibitors (e.g., umifenovir) or vaccine-induced antibodies block viral attachment to receptors or prevent the conformational change required for membrane fusion.